Author/year
|
Age/sex
|
Thymoma type
|
Hematological malignancy
|
Co-immune disorder
|
Clinical course
|
---|
Szolkowska et al. 2017 [5]
|
52, male
|
B1/B2
|
SLL
|
–
|
CR at 2 years
|
Chen et al. 2015 [6]
|
74, male
|
A
|
DLBCL
|
–
|
CR at 7 months
|
Ito 2015 [7]
|
62, male
|
AB
|
T-LBL
|
–
|
CR at 1 year
|
Fraser et al. 2012
|
59, male
|
B1
|
PTCL, NOS
|
–
|
Death at 7 months
|
Yamato et al. 2006 [8]
|
59, male
|
B3
|
DLBCL
|
–
|
CR at 5 months
|
Rovera et al. 2003 [9]
|
65, male
|
AB
|
T-LBL
|
–
|
Death at 8 months
|
Khoury et al. 2003 [10]
|
62, male
|
NA
|
CLL/SLL
|
NA
|
NA
|
Friedman et al. 1994 [11]
|
95, male
|
NA
|
T-LBL
|
–
|
Death at 10 days
|
The present case, 2020
|
81, female
|
B1
|
DLBCL
|
MG
|
CR at 14 months
|
- CLL chronic lymphocytic leukemia, CR complete remission, DLBCL diffuse large B-cell lymphoma; MG myasthenia gravis, NA not available, PTCL peripheral T-cell lymphoma, NOS not otherwise specified, SLL small lymphocytic lymphoma, T-LBL T lymphoblastic lymphoma/leukemia